Core Insights - Human fibrinogen is recognized globally for its clinical application value in regulating coagulation function, with increasing demand driven by aging populations and rising living standards [1][13] - The market size for human fibrinogen in China is projected to grow from 1.529 billion yuan in 2021 to 2.15 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 12.0% [1][13] - The production process of human fibrinogen is expected to improve with technological advancements, leading to enhanced product quality and continuous market growth [1][13] Industry Overview - Fibrinogen is a key substrate in the coagulation and hemostasis process, essential for maintaining normal coagulation and promoting platelet aggregation [3] - Human fibrinogen is derived from healthy human plasma, processed to remove viruses, and is used as an effective replacement therapy for fibrinogen deficiency [3] - The normal concentration of fibrinogen in the human body is maintained at 2-4 g/L, and it is crucial for correcting hypofibrinogenemia and improving coagulation disorders [3] Market Dynamics - The number of blood collection stations and plasmapheresis stations in China is increasing, with 3 new stations approved and 17 new operational stations in 2024, leading to a steady rise in plasma collection [8] - The total plasma collection volume in 2024 is expected to reach 13,400 tons, a year-on-year increase of 10.94%, with major companies like Tian Tan Biological, Taibang Biological, and Shanghai Raist accounting for approximately 80% of the domestic plasma collection [8] - The growth in the number of medical institutions, driven by an aging population and increased health awareness, is expected to boost the demand for human fibrinogen [11] Competitive Landscape - The human fibrinogen industry is attracting significant attention from capital markets, with increasing competition as more companies enter the field [17] - Key players in the industry include Huaren Boya Biological Pharmaceutical Group, Shanghai Raist Blood Products, and Beijing Tiantan Biological Products, among others [17][18] Future Trends - Continuous government policy support is expected to benefit the human fibrinogen market, with initiatives aimed at improving the quality and safety of blood products [22] - Companies are focusing on optimizing production processes and enhancing plasma utilization rates, which will drive overall industry progress [23] - The expansion of medical insurance coverage and rising consumer spending on healthcare are anticipated to gradually increase the market demand for human fibrinogen [24]

近年来，血液制品行业并购案例频发。就在近日，国药集团（01099.HK）旗下的中国生物发布公 告称，拟46亿元收购派林生物（000403.SZ）21.03%的股权，属于高溢价收购。 本次交易完成后，行业老大吞下行业老三，国药系坐拥154个浆站，这将重构血制品行业格局。而 拥有38个血浆站、年采浆量超过1400吨的派林生物多次易主后，将正式被纳入央企版图。 多次易主背后是内讧不断 回顾过往会发现，派林生物是一家因管理内讧而耽误崛起的巨头企业。从三九生化到振兴生化，又 改为双林生物，最后才是如今看到的派林生物，这名称变化的背后是公司的多次易主的历史痕迹。 派林生物最初并不属于血制品行业，其前身系宜春工程机械股份有限公司，1996年经中国证监会批 准在深交所上市，控股股东是宜春工程机械股份有限公司；两年后变更为三九企业集团；2002年控制权 又转到了三九医药股份有限公司手里； 2007年，振兴集团有限公司接盘；2018年，杭州浙民投天弘投资合伙企业（有限合伙）（简称"浙 民投"）斥资30亿元成为新主人，更名为双林生物；跨界布局血制品领域也只是在2021年，当时该公司 用13家浆站的双林生物收购了拥有10家浆站的哈尔 ...

证券研究报告：医药生物|行业周报 发布时间：2025-06-16 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7895.79 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 周最低 | | 6070.89 | 行业相对指数表现 2024-06 2024-08 2024-11 2025-01 2025-04 2025-06 -14% -11% -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 近期研究报告 推荐标的：英科医疗、迈普医学、怡和嘉业、微电生理、 拱东医疗、派林生物、益丰药房、大参林、康臣药业、佐力药 业、桂林三金、天士力、新里程、美年健康、国际医学。 《政策支持上市公司通过并购重组高 质量发展，行业整合持 ...

检验 全面阻击病毒 保证血液安全 当满载爱心的血袋从街头采血点送至北京市红十字血液中心，一场与时间的赛跑即刻启动。 每袋血液都携带专属"身份证"：初检血型、操作员信息、用于信息识别的二维码，以及两支不同颜 色的血样试管。它们抵达的第一站就是接血区。扫描录入信息后，血液样本试管会送至检验科进行核酸 和血清学检测，血袋则同步被送至三层的成分科进行血液产品制备。 血液是救命神器，但稍有不慎也可能是致病元凶。艾滋病、梅毒、乙肝、丙肝等疾病都能通过血液 传播。为了便于检测，每份血液带有两支不同规格的血样试管，绿帽试管血样用于做血清学检测，筛查 乙肝、丙肝、艾滋病病毒、梅毒、转氨酶以及ABO、RhD血型确定。紫帽试管血样则用于核酸检测，筛 查血液中病毒遗传物质。实验室内，两排离心机始终保持工作状态。检验科工作人员告诉北青报记者， 血液样本要离心15至20分钟，将血细胞与血浆精确分离。随后，这些试管被送至不同的大型检测设备 中，开展核酸检测和血清学检测，好比发现和对抗病毒的两把"狙击枪"。 每条检测结果的背后都是对生命的负责。为了保证检测结果的准确性，所有标本都要在这里用不同 厂家的试剂检测两遍。经历接收、离心、检测、报告 ...

Core Viewpoint - The acquisition of 21.03% of shares in Palin Biotech by China National Pharmaceutical Group (Sinopharm) marks a significant shift in control, with the company expected to become part of the national team in the blood products industry [1][4][12]. Group 1: Acquisition Details - Palin Biotech's controlling shareholder will change from Shengbang Yinghao to China National Pharmaceutical Group, with the actual controller shifting from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to Sinopharm [1][4]. - The transaction price for the share transfer is approximately 38.44 billion yuan, which includes interest calculated at an annual rate of 9% from March 20, 2023, until the signing of the transaction documents [8][10]. - The share transfer price represents a premium of about 47.40% over the closing price of 16.96 yuan per share on the day before the agreement was signed [6][8]. Group 2: Financial Performance and Growth - Palin Biotech has shown steady revenue growth, with reported revenues of 19.72 billion yuan, 24.05 billion yuan, 23.29 billion yuan, and 26.55 billion yuan from 2021 to 2024, respectively [14]. - The net profit attributable to the parent company has also increased, with figures of 3.91 billion yuan, 5.87 billion yuan, 6.12 billion yuan, and 7.45 billion yuan for the same years [14]. - The company is expected to distribute a total of 5.12 billion yuan in cash dividends in 2023 and 2024, with Shengbang Yinghao projected to receive over 1 billion yuan in dividends [10]. Group 3: Industry Context and Competition - The acquisition raises potential concerns regarding competition, as both Palin Biotech and Tian Tan Biological Products, a subsidiary of Sinopharm, operate in the same blood products sector [2][15]. - The integration of Palin Biotech into Sinopharm's portfolio will increase the number of listed companies under the Sinopharm umbrella to eight, enhancing its presence in the healthcare market [11][12]. - The strategic focus of Palin Biotech remains on blood products, with ongoing efforts to expand production capacity and improve operational efficiency [14][15].

控股股东或变更为中国生物 资料显示，中国生物是国药集团的子公司，国药集团持股比例为95.36%。公开资料显示，国药集团是 由国务院国资委直接管理的以生命健康为主业的中央企业，经营业务涵盖科技研发、工业制造、物流分 销、零售连锁、医疗健康等大健康全产业链。 根据协议条款，股份转让价格按照胜帮英豪2023年3月20日收购派林生物控制权时的交易本金38.44亿元 计算。在此基础上，还需加上该本金在利息期间按年化单利9%计算的利息。利息期间从2023年3月20日 起算至本次交易正式文件签署日，不足一年的按日计算，每年按365日计算。 派林生物提示，胜帮英豪与中国生物签署《收购框架协议》后，中国生物将依据《收购框架协议》开展 尽职调查工作，尽职调查完成后，各方将确定是否签署协议，本次交易存在后续协议签署时间待定、未 能签署及交易无法达成的风险。另外，本次交易尚需取得深圳证券交易所的合规性确认意见并在中国证 券登记结算有限责任公司深圳分公司办理股份过户登记手续以及完成相关法律法规要求可能涉及的其他 批准，该事项能否最终实施完成及实施结果尚存在较大不确定性。本次公司控制权拟变更事项不会对公 司的正常生产经营造成不利影响，不 ...

Core Viewpoint - The blood products industry is undergoing significant consolidation, with the leading player, China National Pharmaceutical Group (Sinopharm), acquiring the third-ranked company, Pailin Biotech, which will further solidify its market position [2][3]. Group 1: Acquisition Details - Pailin Biotech's controlling shareholder, Shengbang Yinghao, signed an acquisition framework agreement with China National Pharmaceutical, intending to transfer 21.03% of its shares [2]. - The estimated transaction price for the share transfer is approximately 4.612 billion yuan, translating to a per-share price of about 29.99 yuan, representing a premium of approximately 76.83% compared to the last closing price before suspension [2]. - The acquisition is still subject to due diligence and final agreement on transaction terms, with the final payment arrangements yet to be clarified [2]. Group 2: Market Impact - The acquisition will reshape the competitive landscape of the blood products sector, with Sinopharm's market dominance being reinforced by its ownership of three major blood product companies, including Tian Tan Biological and Wei Guang Biological, totaling 154 plasma collection stations [3][10]. - Following the announcement, Pailin Biotech's stock rose by 1.06%, while Tian Tan Biological and Wei Guang Biological experienced slight declines [3]. Group 3: Historical Context - Pailin Biotech has undergone multiple ownership changes, with its focus shifting to the blood products sector since 2007, culminating in its rebranding after acquiring another company in 2021 [4][5]. - The company has faced internal conflicts and governance issues, particularly during its transition to new shareholders, which have impacted its operational stability [5][9]. Group 4: Industry Dynamics - The blood products market is characterized by a "three-legged" competitive structure, with Sinopharm, China Resources, and Haier Group as the main players, but Sinopharm has established a significant lead in both the number of plasma stations and collection volume [10][15]. - As of 2024, Sinopharm's total plasma collection volume is 4,743 tons, accounting for approximately 35.4% of the industry, with further growth expected as additional stations become operational [10][16].

21世纪经济报道记者韩利明上海报道 仅约两年时间，派林生物（000403.SZ）的控制权再迎更迭。 日前，派林生物发布公告称，其控股股东胜帮英豪与中国生物签署了《收购框架协议》。根据协议，胜 帮英豪拟将其所持派林生物 21.03% 的股份转让给中国生物，此次交易将以现金方式完成。 不过，派林生物同时提示，中国生物将对其开展尽职调查，后续协议的签署时间尚未确定，甚至存在无 法签署协议及交易最终无法达成的风险。若该交易能够顺利完成，派林生物的控股股东将变更为中国生 物，实际控制人也将由陕西省人民政府国有资产监督管理委员会变更为中国医药集团有限公司（下 称"国药集团"）。 对此，派林生物解释主要受派斯菲科二期产能扩增停产影响，导致产品供应量同比下降。不过派林生物 在5月20日接受投资者调研时表示，"派斯菲科二期扩能验收后已于2025年3月初正式投产，子公司广东 双林产能提升预计于6月投产，公司扩能后产能将提升至超3000吨。" 血液制品行业的竞争中，企业规模取决于采浆量规模，而盈利能力则取决于产品数量。2024年，派林生 物采浆量已超1400吨，作为千吨级血制品企业第一梯队的成员，旗下广东双林和派斯菲科产品品种合计 ...

6月9日晚间，派斯双林生物制药股份有限公司发布公告称，公司控股股东共青城胜帮英豪投资合伙企业 （有限合伙）与中国生物技术股份有限公司签署了《收购框架协议》，胜帮英豪拟将所持派林生物 21.03%股份转让给中国生物。 公告显示，派林生物的转让价格将基于胜帮英豪2023年3月份收购控制权时的本金38.44亿元，加上按年 化单利9%计算的利息。 若本次交易顺利完成，派林生物的控股股东将变更为中国生物，实际控制人将由陕西省人民政府国有资 产监督管理委员会变更为中国医药集团有限公司（"国药集团"）。 而国药集团是以生命健康为主业的央企，拥有1600余家成员企业，包括国药控股、国药股份、国药一 致、天坛生物、中国中药、国药现代、太极集团等上市公司。 国药集团此次入主派林生物或是受到血液制品行业份额存在空缺的影响。据了解，血液制品行业监管极 为严格。自2001年起，我国对血液制品生产企业实行总量控制，不再批准新设企业，导致国内血浆供应 长期偏紧，存在巨大缺口。 根据市场研究机构统计数据，2024年我国血液制品市场规模达到600亿元，预计到2030年我国血液制品 市场规模将达到950亿元，行业未来成长空间巨大。 值得注意的是 ...

Group 1 - Lingnan Holdings plans to publicly transfer 3.92% equity of Guangzhou World Wonder at a base price of 23.6576 million yuan, focusing on core business development [1] - Guangkang Biochemical's chlorantraniliprole product has a designed capacity of 10 tons/year but has not yet been produced, with expected minor contribution to overall performance [1] - Palin Bio's controlling shareholder intends to transfer 21.03% of shares to China National Biological, changing the controlling shareholder and actual controller [1][2] Group 2 - Haimer Technology is planning a change of control, leading to a temporary stock suspension for up to two trading days [1] - *ST Zhongdi's stock will be suspended for one day and will resume trading with a change in risk warning status [1] - Jiahua Intelligent's shareholder plans to reduce holdings by up to 1% of total shares due to personal funding needs [5] Group 3 - Bosi Software's director plans to reduce holdings by up to 0.22% of total shares for personal funding needs [6] - Hanjia Design's director intends to reduce holdings by up to 35.6 million shares, representing 0.1577% of total shares [7] - Nanfang Energy plans to invest approximately 51.9788 million yuan in distributed photovoltaic power stations, expecting related transaction amounts to reach 99.3685 million yuan over 25 years [8] Group 4 - Tian Tie Technology's subsidiary temporarily halted production due to steam supply issues, expected to last about one month [9] - Haiguang Information plans a share swap to absorb and merge with Zhongke Shuguang, with stock resuming trading [11] - Tianyima is planning to acquire controlling interest in Xingyun Kaiwu, leading to a stock suspension for up to 10 trading days [12] Group 5 - Xinhua Group's chairman resigned, and Wang Gengyu was elected as the new chairman [13] - Zongyi Co. plans to invest 220 million yuan in Jilai Microelectronics, aiming for a controlling stake post-investment [14] - Zhongying Electronics' controlling shareholder will change to Zhinen Industrial Electronics, with stock resuming trading [16] Group 6 - Huayang Lianzhong plans to jointly invest in a new company with its controlling shareholder, with a registered capital of 402 million yuan [19] - Gaomeng New Materials' chairman and executives plan to reduce holdings by a total of 0.41% of total shares [20] - Beifang Changlong intends to acquire 51% of Henan Zhongsheng for approximately 102 million yuan, expanding its business scope [21]